“With the successful execution of the Phase 1 and 2 studies, in collaboration with our partner GSK, we are well on our way to advancing our most complex COVID-19 and seasonal influenza systems into the later stages of clinical development,” said Dr. Anne Schulz, Ph. D. , Ph. D. , Ph. D. ,Myriam. Mendila, Chief Development Officer at CureVac. ” The effect of mRNA generation continues to reshape health care. As a company at the forefront of uninterrupted mRNA innovation, we are excited to bring potentially disruptive vaccine applicants to market.
As part of the COVID-19 Co-Development Program, enrollment in the ongoing Phase 2 study ended with 427 participants randomized after the first participant won one dose in August 2023. The study evaluates the protection and immunogenicity of a single other booster dose of two modified COVIDs. -19 mRNA. 19 vaccine applicants: the monovalent candidate, CV0601, encoding the spike protein of the BA. 4-5 omicron variant and the bivalent candidate, CV0701, encoding the spike protein of the BA. 4-5 omicron variant, as well as the original SARS vaccine. CoV-2 strain. Vaccine applicants are compared to a legal or bivalent comparator vaccine against legal COVID-19. Interim data for phase 2 is expected in early 2024.
As part of the joint progression program against seasonal influenza, the first participant won a dose in the phase 2 of the combined phase 1/2 study, following the presentation of a promising vaccine candidate based on positive interim data from phase 1 announced in September. 12, 2023. , multivalent candidate codes for antigens corresponding to all influenza strains by WHO. In phase 1 of the study it was decided to compare a full set of multivalent and modified mRNA seasonal influenza vaccine applicants with up to eight different mRNA constructs depending on the candidate. In Phase 2, the chosen candidate will be tested in more young and older adults at other dose levels compared to the licensed age-appropriate seasonal influenza comparator vaccines. Data is expected for 2024.
CureVac (Nasdaq: CVAC) is a global biopharmaceutical corporation in the field of messenger RNA (mRNA) generation, with over 20 years of experience in the progression, optimization and production of this flexible biological molecule. medical purposes. The principle of CureVac’s patented generation is the use of optimized mRNA as a knowledge carrier to instruct the human body to produce its own proteins capable of combating a wide diversity of diseases. In July 2020, CureVac entered into a collaboration with GSK to jointly expand new infectious disease prophylactic vaccine products based on CureVac’s second-generation mRNA generation. This collaboration subsequently extended to the progression of second-generation COVID-19 vaccine applicants and changed mRNA vaccine technologies. Building on its proprietary generation, CureVac has built a broad clinical portfolio in the spaces of prophylactic vaccines, anti-cancer treatments, anti-marginal treatments, and rare disease treatments. CureVac N. V. is headquartered in Tübingen, Germany, and has more than 1,100 employees at locations in Germany, the Netherlands, Belgium, Switzerland and the United States. More information can be obtained at www. curevac. com.
CureVac Media & Investor Relations
Dr. Sarah Fakih, Vice President of Corporate Communications and Investor Relations
Phone: 7071 9883-1298
M: 49 160 496949
sarah. fakih@curevac. com
This press release includes statements that constitute “forward-looking statements” as that term is explained in the Private Securities Litigation Reform Act of 1995, including statements that express opinions, expectations, ideals, plans, objectives, assumptions or projections. by CureVac N. V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc. , CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Nederland B. V. (the “Company”) in respect of long-term occasions or performance occasions. effects, contrary to statements that reflect old facts. The examples come with a discussion of the potential effectiveness of the company’s vaccine and remedy applicants, as well as the company’s strategies, financing plans, expansion opportunities, and expanding market position. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “specify. ” expect”, “possibly”, “will”, “would”, “may also simply”, “prospective”, “intends” or “deserves”, the negative form of those terms or explicit similar ones. Forward-looking statements are based on management’s existing ideals and assumptions and the Company’s current configuration. However, such forward-looking statements are not guarantees of the Company’s performance and you should not place undue reliance on them. Forward-looking statements are subject to a variety of risks, uncertainties and other varying circumstances, including negative global economic situations and continued instability and volatility in global money market positions, the ability to discharge financing, the ability to conduct preclinical studies and the current and long-term. execute clinical trials, timing, expense and uncertainty of regulatory approval, dependence on third parties and collaboration partners, ability to commercialize products, ability to manufacture products. Arrange conceivable adjustments to existing and proposed legislation, regulations and government policies, pressures similar to festival expansion and consolidation within the business. industry, the effects of the COVID-19 pandemic on the Company’s business and operational effects, the ability to manage expansion, dependence on key personnel, dependence on intellectual property coverage, the ability to make certain defense patient and fluctuations in operating effects due to the effect of exchange rates or other factors. Such dangers and uncertainties could cause the statements to be misleading and readers are cautioned not to place undue reliance on such statements. Many of these hazards are beyond the Company’s control and may also cause their actual effects to differ materially from those expected to occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not assume, and in particular disclaims, any legal responsibility to update such statements or to publicly announce the effects of any revisions to such statements to reflect long-term events or developments, unless required by law.
For more information, please refer to the Company’s reports and documents filed with the U. S. Securities and Exchange Commission. U. S. Securities and Exchange Commission (SEC). You can download those documents by visiting EDGAR at the SEC in www. sec. gov.